Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genetic Technologies (GTG) has signed a research pact with a pharma firm to co-develop a new cancer profiling product and to expand their presence in the field of personalized medicine.
Subscribe to our email newsletter
The tie up allows GTG to utilize some of its intellectual property and expertise for the development of specific and novel genetic oncology profiling systems to target chemotherapy in late stage cancer patients.
Under the agreement, GTG will to conduct a clinical oncology study and offer these results to its collaboration partner.
GTG CEO Paul MacLeman said this collaboration is a validation of GTG’s capabilities in the area of very low signal to noise nucleic acid analysis.
"The need for companion diagnostics to determine effective treatments for cancer patients is well established," MacLeman said.